Alzheimer
Brain diseases
Research
Tau
APP
Abeta
VCDN group
flag

Aging

ALS

ALS/PDC Guam
AGD
Bri
CBD
DLDH
DM1
Down S
GSS
FTD
FTDP-17
Huntington
Hallenvorden
IBM
Lewy BD
MSA
NPiD c
Parkinson D Guadeloupe
Parkinson
Dementia  in Parkinson 
Pick
Prion
PSP
PEP
Semantic  D
SSP
  ToD

Publications 1996


1996-1 BUEE L, PEREZ-TUR J, LEVEUGLE B, BUEE-SCHERRER V, MUFSON EJ, LOERZEL AJ, CHARTIER-HARLIN M-C, PERL DP, DELACOURTE A, HOF PR. Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathologic changes. Acta neuropathol, 1996, 91:247-253.


1996-2 BUEE-SCHERRER V., HOF PR, BUEE L, LEVEUGLE B, VERMERSCH P, PERL DP, OLANOW CW, DELACOURTE A. Hyperphosphorylated Tau protein doublets in corticobasal degeneration and Pick's disease. Acta Neuropathol. 1997, 91: 351-359.


1996-3 BUEE-SCHERRER, CONDAMINES O, MOURTON-GILLES C, JAKES R, GOEDERT M, PAU B, DELACOURTE A. AD2, a phosphorylation-dependent monoclonal antibody directed against Tau proteins found in Alzheimer's disease. Molecular Brain Research. 39:79-88.


1996-4 CAILLET-BOUDIN ML, DELACOURTE A. Induction of a specific Tau Alzheimer epitope in SY-5Y neuroblastoma cells. Neuroreport. 1996, 8: 307-310.


1996-5 COURATIER P., LESORT M., MOURTON- GILLES C. DELACOURTE A., HUGON J. Neuronal protein kinase C activation enhances phosphorylated Tau protein immunoreactivity. Neurosciences Letters. 1996, 203:155-158.


1996-6 Delacourte A, Robitaille Y, Sergeant. N, Buée L, Hof P, Wattez A, Laroche-Cholette A, Mathieu J, Chagnon P, Gauvreau D. Specific pathological tau protein variants characterize Pick's disease. J. Neuropathol. Exp. Neurol.1996;55:151-159.


1996-7) LAMBERT JC, PEREZ-TUR J, DUPIRE M-J, DELACOURTE A, FRIGARD B, CHARTIER-HARLIN MC. Analysis of the ApoE alleles impact in Down’s syndrome. Neuroscience Letters, 1996, 220:1-4


1996-8 LEFRANC D, VERMERSCH P, DALLONGEVILLE J, DAEMS-MONPEURT C, PETIT H, DELACOURTE A. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer’s disease. Neuroscience Letters, 1996; 212:91-94.


1996-9 Perez-Tur J., Wavrant-De Vriez F., Lambert, J.C., Chartier-Harlin M.C., Delacourte A., Dupire Mj, Frigard B., Pasquier F., Petit H., Vermersch P. The PS1 polymorphism is not associated with late onset Alzheimer's disease in a French population.Lancet, 1996;347:1560-1561.


1996-10 SOULIÉ C, LEPAGNOL J, DELACOURTE A, CAILLET-BOUDIN M.L. Déphosphorylation studies of SKNSH-SY 5Y cell Tau proteins by endogeneous phosphatase activity. Neuroscience Letters. 206:189-192.


1996-11 Vermersch P., Sergeant N., Ruchoux M.M., Hofmann-Radvanyi H.,Wattez, A., Dewailly P., Petit H., Delacourte A. Specific Tau variants in the brain from patients with myotonic dystrophy. Neurology. 1996, 47:711-717.

 

Acta Neuropathol (Berl) 1996;91(3):247-253

Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes.

Buee L, Perez-Tur J, Leveugle B, Buee-Scherrer V, Mufson EJ, Loerzel AJ, Chartier-Harlin MC, Perl DP, Delacourte A, Hof PR

Apolipoprotein E (Apo E) has been recently identified within amyloid deposits and neurofibrillary tangles in the brains of Alzheimer's disease (AD) patients. A strong association of the Apo E epsilon 4 allele with higher risk of developing AD has also been reported. In the present study, the distribution of Apo E and the possible relationship between Apo E alleles and neuropathological alterations were analyzed in a series of Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC) cases, a neurodegenerative condition characterized neuropathologically by widespread, severe neurofibrillary tangle formation but rare amyloid deposits. ApoE immunoreactivity was consistently observed in both type of lesions in these cases. Compared to tau protein immunoreactivity, there were generally fewer Apo E-immunoreactive neurofibrillary tangles, particularly in the deep layers of the neocortex and in the hippocampus. Genotype analysis revealed that the epsilon 4 allele frequency was 5.9%, the epsilon 3 allele frequency 88.2%, and the epsilon 2 allele frequency 5.9% in this series. Recent data suggest that the Apo E4 variant may induce amyloidogenesis, while E2 could have a neuroprotective role. However, the rare Guamanian patients with amyloid deposits in cortical areas were not related to the epsilon 4 allele, since all cases with senile plaques were epsilon 3/epsilon 3. In addition, compared to unaffected Guamanian cases and other Asian-Pacific populations previously reported, the observed low frequency of the epsilon 2 allele in the present cases, which may be consistent with the notion that this allele, may represent a neuroprotective factor in several neurodegenerative disorders. The present data indicate that there is a strong interaction between Apo E deposition and neurofibrillary changes in Guamanian ALS-PDC.

PMID: 8834536, UI: 96431454